Net Cash Provided by (Used in) Financing Activities of CNBX Pharmaceuticals Inc. from 30 Nov 2011 to 30 Nov 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
CNBX Pharmaceuticals Inc. quarterly and annual Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 30 Nov 2011 to 30 Nov 2025.
  • CNBX Pharmaceuticals Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 30 Nov 2025 was $40,000, a 33% increase year-over-year.
  • CNBX Pharmaceuticals Inc. annual Net Cash Provided by (Used in) Financing Activities for 2025 was $160,000, a 482% increase from 2024.
  • CNBX Pharmaceuticals Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $27,512, a 72% decline from 2023.
  • CNBX Pharmaceuticals Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $100,000, a 74% decline from 2022.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

CNBX Pharmaceuticals Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $40,000 +$10,000 +33% 01 Sep 2025 30 Nov 2025 10-Q 14 Jan 2026 2026 Q1
Q4 2024 $30,000 +$5,007 +20% 01 Sep 2024 30 Nov 2024 10-Q 14 Jan 2026 2026 Q1
Q4 2023 $24,993 +$24,993 01 Sep 2023 30 Nov 2023 10-Q 13 Jan 2025 2025 Q1
Q4 2022 $0 01 Sep 2022 30 Nov 2022 10-Q 12 Jan 2024 2024 Q1
Q4 2020 $0 $0 01 Sep 2020 30 Nov 2020 10-Q 14 Jan 2021 2021 Q1
Q4 2019 $0 -$7,149,811 -100% 01 Sep 2019 30 Nov 2019 10-Q 14 Jan 2021 2021 Q1
Q4 2018 $7,149,811 +$7,171,811 01 Sep 2018 30 Nov 2018 10-Q 14 Jan 2020 2020 Q1
Q4 2017 $22,000 -$427,980 -105% 01 Sep 2017 30 Nov 2017 10-Q 17 Jan 2019 2019 Q1
Q4 2016 $405,980 01 Sep 2016 30 Nov 2016 10-Q 16 Jan 2018 2018 Q1
Q4 2012 $0 $0 01 Sep 2012 30 Nov 2012 10-Q 14 Jan 2013 2013 Q1
Q4 2011 $0 01 Sep 2011 30 Nov 2011 10-Q 14 Jan 2013 2013 Q1

CNBX Pharmaceuticals Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $160,000 +$132,488 +482% 01 Sep 2024 31 Aug 2025 10-K 01 Dec 2025 2025 FY
2024 $27,512 -$72,488 -72% 01 Sep 2023 31 Aug 2024 10-K 01 Dec 2025 2025 FY
2023 $100,000 -$289,858 -74% 01 Sep 2022 31 Aug 2023 10-K 29 Nov 2024 2024 FY
2022 $389,858 -$2,066,892 -84% 01 Sep 2021 31 Aug 2022 10-K 30 Nov 2023 2023 FY
2021 $2,456,750 +$2,456,750 01 Sep 2020 31 Aug 2021 10-K 30 Nov 2022 2022 FY
2020 $0 -$7,217,270 -100% 01 Sep 2019 31 Aug 2020 10-K 29 Nov 2021 2021 FY
2019 $7,217,270 +$5,774,270 +400% 01 Sep 2018 31 Aug 2019 10-K 04 Nov 2020 2020 FY
2018 $1,443,000 -$2,894,909 -67% 01 Sep 2017 31 Aug 2018 10-K 29 Nov 2019 2019 FY
2017 $4,337,909 +$4,223,909 +3705% 01 Sep 2016 31 Aug 2017 10-K 29 Nov 2018 2017 FY
2016 $114,000 01 Sep 2015 31 Aug 2016 10-K 08 Dec 2017 2017 FY
2013 $100,000 01 Sep 2012 31 Aug 2013 10-K 29 Nov 2013 2013 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.